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Susceptibility to infectionIndividual differences in susceptibility to human immunodeﬁciency virus type 1 (HIV-1) infection have been of
interest for decades. We aimed to determine the contribution of large isoform of Mammalian DnaJ (MRJ-L), a
HIV-1 Vpr-interacting cellular protein, to this natural variation. Expression ofMRJ-L inmonocyte-derivedmacro-
phageswas signiﬁcantly higher inHIV-infected individuals (n=31) than their uninfected counterparts (n=27)
(p = 0.009). Fifty male homosexual subjects (20 of them are HIV-1 positive) were further recruited to examine
the association between MRJ-L levels and occurrence of HIV infection. Bayesian multiple logistic regression re-
vealed that playing a receptive role and increased levels of MRJ-L in macrophages were two risk factors for
HIV-1 infection. A 1% rise in MRJ-L expression was associated with a 1.13 fold (95% CrI 1.06–1.29) increase in
odds of contracting HIV-1 infection. Ex vivo experiments revealed that MRJ-L facilitated Vpr-dependent nuclear
localization of virus. Infection of macrophage-tropic strain is a critical step in HIV-1 transmission. MRJ-L is a crit-
ical factor in this process; hence, subjects with higher macrophage MRJ-L levels are more vulnerable to HIV-1
infection.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
More than 30 million individuals worldwide are currently infected
with human immunodeﬁciency virus type 1 (HIV-1), the cause of
acquired immunodeﬁciency syndrome (AIDS), with 1.7 million deaths
occurring from AIDS in 2011 (World Health Organization, 2011). Cur-
rently, combination antiretroviral therapy is successful in controlling
the disease progression of HIV infection. However, antiretroviral thera-
py is known to be associated with deleterious complications such as
metabolic derangement (Paula et al., 2013). Cessation of antiretroviral
therapy is not feasible as it may lead to viral rebound and disease pro-
gression (Costiniuk et al., 2013). Moreover, lifelong antiretroviral treat-
ment poses a great economic burden to society as well as the family.
Alternative strategies to control HIV-1 infection are highly desir-
able. These may include manipulation of the immune response and
other host factors. Prophylactic HIV-1 vaccines do not appear to showTaipei 10002, Taiwan.
ork.
. This is an open access article underimmediate promise, following the failure of a recent clinical trial
(Cohen, 2007). A therapeutic HIV-1 vaccine has produced some positive
results but still requires further development before it can be brought to
the clinic (Pollard et al., 2014). Manipulation of host proteins is currently
being evaluated, as demonstrated by a study tomodify the CCR5 receptor
(Didigu et al., 2014). This is a promising way to complement the current
antiretroviral therapy. Nevertheless, its success relies on our understand-
ing of the interaction between HIV-1 and cellular proteins.
It has long been of interest in the ﬁeld of infectious diseases that dif-
ferent individuals show varying degrees of susceptibility to infection.
This variation may be due to differences in host protein expression.
For example, one of the most well-known susceptibility-determining
factors for HIV infection is the CCR5 co-receptor. A deletion of 32 bp in
the CCR5 receptor confers amuch reduced susceptibility to HIV-1 infec-
tion for the host (Liu et al., 1996; Dean et al., 1996; Samson et al., 1996).
A number of other enhancing and restrictive factors on HIV-1 replica-
tion have been proposed, including TRIM5α, APOBEC3 family, BST-2/
tetherin, HLA-G, and microRNAs (Lever and Lever, 2011; da Silva et al.,
2014; Napuri et al., 2013). However, whether they affect individual sus-
ceptibility to HIV-1 infection remains elusive (Imahashi et al., 2014).the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ed by viral entry and replication.Many cellular factors interactwith viral
genes for the completion of the replication cycle and production of ma-
ture virions. We reasoned that cellular and viral protein interactions
may contribute to varying degrees of susceptibility to viral infection.
Hence, we examined Vpr-associated cellular proteins and studied
their roles in human HIV-1 infection. In a previous study, by yeast-
two-hybrid assay we identiﬁed several cellular proteins that interact
with HIV-1 Vpr (Yedavalli et al., 2005). Of them, DNAJB6 is a homolog
of heat shock protein 40 (HSP40), and has two splice isoforms: the
large form MRJ-L and the small form MRJ-S (Hanai and Mashima,
2003). Prompted by the notion that DNAJ is a heat shock protein
which may contribute to HIV-1 replication, we investigated the expres-
sion of DNAJB6 in lymphocytes and monocyte-derived macrophages
(MDMs) which are considered the major targets of early HIV-1 infection.
2. Materials and Methods
2.1. Participant Recruitment and Serologic Screening for HIV Infection
Self-completed questionnaires and blood samples were collected
from anonymous participants at commercial male homosexual venues
of Taipei andNewTaipei City onweekends. The questionnaires included
measures of demographics, HIV testing history and sexual risk behavior
(Supplementary Table 1). A total of 1200 study participants received
pre-test counseling, were informed about the purpose of this study
and gave written informed consent. HIV diagnosis wasmade using a re-
combinant HIV enzyme immunoassay (Murex Diagnostics Limited,
Dartford, UK). Positive test results were conﬁrmed by HIV western
blot 2.2 (Genelab Technologies, Inc., Singapore). In addition, positive
blood samples were tested for HIV-1 subtype. Based on the regular
blood sampling every 3 months, 89 participants were infected with
HIV-1. Of the subjects who were identiﬁed to be seroconverted within
prior 6 months, 20 of themwere recruited to join this MRJ-L evaluation
study. Another 30 uninfected subjects were randomly recruited as con-
trols. This studywas conductedwith the approval of the institutional re-
view board of the Mackay Memorial Hospital, Taipei, Taiwan.
2.2. Cell Lines and Cell Preparations
After obtaining informed consent, CD4+T lymphocytes and CD14+
monocytes were isolated from PBMCs from healthy donors and HIV-
infected patients by Ficoll-Paque gradient (GE Healthcare Life Sciences,
Pittsburgh, PA, USA) using CD4+/CD14+ magnetic microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Laboratory person-
nel were blind to the identity and HIV-1 infection status of blood donors.
To induce macrophage differentiation, monocytes isolated from donors
were maintained in RPMI1640 supplemented with 10% human AB
serum, 5% fetal bovine serum (FBS), and 50 ng/mL M-CSF (PeproTech,
Rocky Hill, NJ, USA) for seven days. Jurkat cells were cultured in
RPMI1640 supplementedwith 10%FBS. In addition, phytohaemagglutinin
(PHA) was added to stimulate Jurkat cells. THP-1 (a monocyte cell line)
and U937 cells were cultured in RPMI1640 (Life Technologies, Grand
Island, NY, USA) supplemented with 10% FBS and 2 mM DMSO. 293
T cells were cultured in DMEM (Life Technologies) supplemented with
10% FBS. To induce differentiation of U937 cells into macrophage-like
cells, 200 μM phorbol myristate acetate (PMA) mitogen was added to
the culture medium, and the cells were harvested after 48 h.
2.3. Plasmids
The plasmid pEGFP–Vpr was constructed by inserting the Vpr gene
ampliﬁed from the HIV-1 pNL4-3 clone into the appropriate vectors.
The HA-MRJ-L and HA-MRJ-S plasmids were constructed in the pcDNA
vector. The lentiviral expression vector of MRJ-L was constructed in
the pLKO_AS3w.puro vector. The MRJ-L 3′UTR shRNA (shJ8_5′-GCGCAGATGGCTAACTGAGTA) was designed using InvivoGen siRNA Wizard
v3.1 software, andwas constructed in the pLKO.1-puro vector (obtained
from the National RNAi Core Facility, Academia Sinica, Taiwan). All con-
struct identities were conﬁrmed by sequencing the entire insert.
2.4. HIV-1 Virus Production and Viral Infection
293 T cells (2 × 106) were transfected with 2 μg of p125 (M-tropic,
ADA strain) plasmids using Lipofectamine 2000, and the supernatants
were harvested at 48 h post-transfection. Viruses were pretreated
with 2 U/mL DNase I (Life Technologies) at 37 °C for 30min before infec-
tion, and the viral titer was quantiﬁed using the p24 ELISA assay
(PerkinElmer, Waltham, MA, USA). Cells with over-expressed or reduced
levels of MRJ-L were titrated to adjust for equal cell numbers, and 1 × 106
cells were infected with M-tropic strain of HIV-1 (equivalent to 25 ng of
p24 antigen) at 37 °C for 2 h. After washing three times with PBS, cells
were maintained in RPMI1640/2% FBS and half of the medium was re-
placed every three days. Culture supernatants were collected every
three days for quantiﬁcation of p24 antigen by HIV-1 p24 ELISA
(PerkinElmer).
2.5. Statistical Analysis
The signiﬁcance level was set at 0.05, and all p values were two-
tailed. Risk factors for HIV-1 infectionwere analyzed using simple logis-
tic regression, followed by Bayesianmultiple logistic regression because
of sparse data. The simple logistic regression was performed using
the software Stata (version 13, StataCorp, College Station, Texas) or
WinBUGS (version 1.4.3; MRC Biostatistics Unit, Cambridge, England)
when there were sparse data. Bayesian multiple regression analysis
was undertaken using the software package WinBUGS.
2.6. Ethical Research Conduct
This study conformed to the provisions of the 1975 Helsinki Declara-
tion andwas approved by the institutional review board of the National
Taiwan University Hospital (NTUH-201102003RC) and Mackay Memo-
rial Hospital (13MMHIS039). All patients gave written consents before
they participated in this study.
3. Results
3.1. MRJ-L Expression in Macrophages Correlates With HIV-1 Susceptibility
in Primary Human Cells
Based on data from cells of 27 uninfected and 31 HIV-1-infected do-
nors [median agewas 25 years (range, 19–30 years),median CD4 count
was 371/μL (range, 276–656/μL) and median plasma HIV RNA load was
18,400 copies/mL (range, 904–242,000 copies/mL)] as well as from cul-
tured T-cell lines, we noted thatMRJ-Swas found in allmonocytes,mac-
rophages, and cultured cell lines, while MRJ-L was uniformly absent
frommonocytes (Fig. 1a, b). Indeed,MRJ-L proteinwas absent inmono-
cytes from all 27 uninfected donors, whereas macrophages derived
therefrom had varying amounts of MRJ-L (see illustrative results from
donors 1, 2, 3, and 8; and cultured cell lines in Fig. 1b). The MRJ-L
expression level was deﬁned as the ratio of MRJ-L divided by total MRJ
(MRJ-L plus MRJ-S). Intriguingly, HIV-1-infected individuals, compared
with uninfected controls, had statistically higher MRJ-L levels (p= 0.009
by the Mann–Whitney rank sum test; Fig. 1c).
There are two ways to interpret the ﬁnding that macrophages in
HIV-1-infected individuals have higher MRJ-L levels than macrophages
fromuninfected individuals. One interpretation is thatMRJ-L expression
is stochastically variable among individuals and that those with higher
MRJ-L levels aremore susceptible to HIV-1 infection. This would explain
the prevalence of highMRJ-L expressors among HIV-1-infected individ-
uals. The second interpretation is that MRJ-L levels are constitutively
Fig. 1. Expression ofMRJ-L andMRJ-S in cell lines and donor PBMCs. (a)Western blot analysis of endogenousMRJ-L andMRJ-S in various cells. Signiﬁcant amounts of MRJ-L andMRJ-S are
seen in U937, PMA-stimulated U937, Jurkat and PHA-stimulated Jurkat cells (lanes 1–4). PBL (peripheral blood lymphocytes) and PHA-stimulated PBLs from donor 1 express similar
amounts of MRJ-L and MRJ-S (lanes 6–7). Note, however, that monocytes (lane 5) express only MRJ-S, but no MRJ-L. GAPDH was used as a loading control. (b) Western blotting of
MRJ-L and MRJ-S in cells from healthy donors and cell lines. (c) MRJ-L expression in macrophages from 31 HIV-1-infected patients and 27 healthy donors. Signiﬁcantly higher levels of
MRJ-L are expressed inmacrophages fromHIV-1-infected individuals than uninfected controls. Average± SD is shown. p= 0.009 by theMann–Whitney Rank Sum test. (d) HIV-1 infec-
tion does not alter the expression level of MRJ-L in PBL and macrophages from donor 9 (lowMRJ-L) or donor 11 (high MRJ-L). Cells were harvested at day 8 post-HIV-1 infection. Expres-
sion of GAPDH was compared for normalization.
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expression. To distinguish between these two possibilities, we infected
macrophages with HIV-1 and determined MRJ-L levels immediately
after infection aswell as eight days later (Fig. 1d). No signiﬁcant changes
in MRJ-L expression levels were seen in cells infected with HIV-1. This
ﬁnding supports the interpretation that individuals with stochastically
high MRJ-L expression are more susceptible to HIV-1 infection.
3.2. Increased Macrophage MRJ-L Expression is a Signiﬁcant Risk Factor for
HIV-1 Infection Among Men Who Have Sex With Men
To conﬁrm our ﬁndings, we recruited a group of male cohort com-
prised primarily of men who have sex with men (MSM) (96%) with a
mean age of 29 years (range 19–45 years). These study participants
were negative for HIV antibody at baseline and underwent follow-up
HIV testing every threemonths. Among the 1200 subjects being follow-
ed, 20 subjects who were identiﬁed to be seroconverted within prior
6 months were recruited to join this MRJ-L evaluation study. Another
30 uninfected participants were also recruited as controls. There were
no signiﬁcant differences between infected and uninfected individuals
in regard to age, sexual orientation, marital status, occupation, educa-
tion, number of sexual partners, frequency of sexual contact, recreation-
al drug use, and frequency of condom use (Supplementary Table 1).Bayesian multiple logistic regression revealed that playing the re-
ceptive role in unprotected anal intercourse (RUAI) and MRJ-L levels
(Fig. 2) were two independent signiﬁcant risks for HIV-1 infection.
After controlling for other factors, we determined that a 1% rise in
MRJ-L expressionwas associatedwith a 1.13 fold (95% CrI 1.06–1.29) in-
crease in odds of contracting HIV-1 infection. RUAI was linked to a 43.9
fold (95% CrI 2.7–2957) increased odds of HIV-1 infection compared
with insertive unprotected anal intercourse (IUAI) (Table 1 and Supple-
mentary Table 2). Because our data contain several zero cells (i.e. no
subjects in those categories), this sparseness of data yielded large cred-
ible intervals in some analyses.
The distribution of MRJ-L levels in Figs. 1c and 2 showed a bimodal
distribution in the HIV-1 naïve population. To access risks of the general
population for HIV-1 infection, we deﬁned the MRJ-L level as high if the
ratio of MRJ-L divided by total MRJ was N0.4 (one standard deviation
above the average of HIV-1 infected and HIV-1 uninfected individuals,
calculated based on the values in Fig. 2), as low if the ratio was b0.25
(average of HIV-1 uninfected individuals), and as medium if the ratio
was between 0.25 and 0.4. By these measures, of the 50 MSM partici-
pants, 35% of HIV-1 seropositive individuals showed high levels of
MRJ-L expression in contrast to 7% of HIV-1 negative cohorts (Table 1
and Fig. 2). Using Bayesian logistic regression analysis, we found that
subjects with medium levels of MRJ-L had a 13.8 fold (95% credible
Fig. 2. Expression of MRJ-L and MRJ-S in 50 MSM participants. Schematic presentation of
MRJ-L expression inmacrophages from 20 HIV-1 recent infected patients and 30 negative
controls. Signiﬁcantly higher levels of MRJ-L are expressed inmacrophages fromHIV-1 in-
fected individuals (36.71± 8.05%) than uninfected controls (23.65± 12.04%). Average±
SD is shown. p = 0.000 by Mann–Whitney Rank Sum test.
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compared to those with low levels of MRJ-L. The odds increased to
52.5 fold (95%CrI 4–680.9) for subjectswith high levels ofMRJ-L. Bayes-
ian multiple logistic regression (Supplementary Table 2) revealed sub-
jects with medium levels of MRJ-L had a 7.6 fold (95% CI 1.4–69.2)
higher odds of contracting HIV-1 compared with those with low levels
of MRJ-L. The odds increased to 41.5 fold (95% CrI 4.3–705.7) for sub-
jects with high levels of MRJ-L.
3.3. Macrophages With Low Levels of MRJ-L are Resistant to Infection With
Low HIV-1 Inoculum
The above ﬁndings reveal a strong correlation between MRJ-L levels
and odds of HIV-1 infection. To investigate the possibility of a causal re-
lationship,we compared the amount of viral replication inmacrophagesTable 1
Demographic characteristics and MRJ-L expression levels of HIV-1 positive and negative
participants.
HIV-1 (+) HIV-1 (−) Total
N = 20 N = 30 N = 50
n (%) n (%) n (%)
Role and protection during anal intercourse
Exclusively insertive with condom 0 4 (13) 4 (8)
Exclusively insertive without regular condom 0 3 (10) 3 (6)
Exclusively receptive/versatile with condom 6 (30) 9 (30) 15 (30)
Exclusively receptive/versatile without regular
condom
12 (60) 10 (33) 22 (44)
Oral sex 0 (0) 3 (10) 3 (6)
NA 2 (10) 1 (3) 3 (6)
History of having sexually transmitted diseases
No 8 (40) 24 (80) 32 (64)
Yes 2 (10) 0 (0) 2 (4)
NA 10 (50) 6 (20) 16 (32)
MRJ-L/MRJ-L plus MRJ-Sa
Low (≤0.25) 1 (5) 14 (47) 15 (30)
Medium (0.25–0.4) 12 (60) 14 (47) 26 (52)
High (≥0.4) 7 (35) 2 (7) 9 (18)
a The MRJ-L expression levels were deﬁned as the ratio of MRJ-L divided by MRJ-L plus
MRJ-S.with high MRJ-L levels to that in macrophages with low MRJ-L levels.
The cells were infected with equal inocula of either high MOI (Fig. 3a)
or low MOI (Fig. 3b) of the macrophage-tropic (M-trophic) HIV-1 ADA
strain (Khanna et al., 2000). Interestingly, macrophages with high
MRJ-L levels consistently harbored higher levels of HIV-1 replication
than those with low MRJ-L levels (Fig. 3a). In the low MOI group, only
macrophages with high, but not low, MRJ-L levels showed detectable
HIV infection (Fig. 3b).
3.4. Depleting MRJ-L Reduces HIV-1 Infection in Macrophages
Based on the above results, we reasoned that siRNA-knock down of
MRJ-L should reduce HIV-1 replication. To address this, we knocked
down MRJ-L in macrophages with normally high expression levels
(from donor 6) (Fig. 4a, western blot, left). Indeed, knock down of
MRJ-L signiﬁcantly reduced HIV-1 infection (Fig. 4a, virus replication
curves, right). Next, we examined how exogenous MRJ-L expression
would affect virus production in macrophages that naturally have low
levels of this protein. The macrophages from donors 4 and 8 contained
low levels of endogenous MRJ-L. We transduced these cells with a
lentiviral MRJ-L expression vector to raise their MRJ-L levels (Fig. 4b,
western blot, left). This increased MRJ-L expression enhanced HIV-1
replication (Fig. 4b). Thus, our results suggest that higherMRJ-L expres-
sion pivotally augments HIV-1 infection in macrophages.
3.5. MRJ-L Interacts With Vpr and is Required for Its Nuclear Entry
Vpr has been implicated in the nuclear import of the HIV-1 pre-
integration complex. BecauseMRJ is amolecular chaperone,we next ex-
amined if MRJ-L plays a role in assisting Vpr with nuclear entry. To do
this, we co-expressed GFP–Vpr and HA-tagged MRJ-L or MRJ-S in HeLa
cells. We observed that Vpr and MRJ-L co-localized in the nuclei of
cells while Vpr and MRJ-S were seen in the cytoplasm (Fig. 5a). GFP–
Vpr was found exclusively (100%, 30 out of 30) in the nucleus in
shRNA (Scramble) cells. When MRJ-L was knocked down in HeLa cells
(Fig. 5b, c), the majority (83%, 39 out of 47) of transfected GFP–Vpr be-
came cytoplasmic rather than nuclear [Fig. 5c; compare shRNA (MRJ-L)
panels to shRNA (Scramble) panels]. These results indicate that MRJ-L
facilitates the nuclear localization of Vpr, a ﬁnding consistent with re-
sults reported previously on the interaction of MRJ-L with HIV-2 Vpx
(Cheng et al., 2008).
4. Discussion
Many cellular factors participate in the replication of a virus. A better
understanding of the cellular factors involved in viral infection can lead
to better antiviral strategies, especially for a difﬁcult virus like HIV-1.
We are particularly interested in cellular factors that exhibit different
expression patterns between individuals, indicating thepresence of nat-
ural polymorphisms and which could therefore be amenable to manip-
ulationwithout grave adverse effects. Vpr is an important auxiliary gene
of HIV-1 with multiple functions (Yedavalli et al., 2005; Kogan and
Rappaport, 2011). Interestingly, we found that MRJ-L, a cellular protein
interacting with Vpr, is enriched when monocytes differentiate into
macrophages and has varying expression levels among macrophages
from different individuals.
Macrophages play a unique role in HIV-1 infection; among all the
quasi-species of HIV-1 in an infected individual, macrophage-tropic
strains are preferentially transmitted to a new host (van't Wout et al.,
1994; Zhu et al., 1993). When HIV-1 is transmitted to a new host at
the mucosal surface, the virus has to undergo ample local expansion
to enable dissemination to local lymphoid tissues, or the infection is
aborted (Haase, 2010). As macrophages are the primary targets of
HIV-1, the transmitted virus should replicate efﬁciently inmacrophages.
For non-dividing cells such as macrophages, delivery of the HIV-1 pre-
integration complex to the nucleus is a critical and likely rate-limiting
Fig. 3. Expression levels of MRJ-L correlate with HIV-1 viral production. (a, b) Higher expression of MRJ-L increases HIV-1 replication.Macrophages derived from six healthy donors (from
the ﬁrst cohort study described in Fig. 1) with low or high expression levels of MRJ-L were infected with HIV-1 at (a) high MOI (p24 = 5 ng/mL) and (b) low MOI (p24 = 50 pg/mL),
respectively. Virus output, measured by p24 levels in culture supernatant using ELISA, at day 4 and day 8 after the infection.
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this nuclear transport, and the presence of sufﬁcient MRJ-L protein ap-
pears to be essential for Vpr to perform this function.Fig. 4. Expression of MRJ-L contributes to HIV-1 viral production. (a) (upper panel) Schematic
macrophages derived from monocytes of high MRJ-L healthy donors. The transduction efﬁcie
Fig. 1). (Lower left) Knock down of endogenous MRJ-L in monocyte-derived macrophages (MD
at day 8 after the shRNA treatment. GAPDHwas used as a loading control. (Lower right) Virus ou
13, and 16 post-HIV-1 (M-tropic) infection. Data shown represent mean ± SD from triplicat
lentiviral overexpression of MRJ-L in macrophages derived from monocytes of low MRJ-L healt
at day 6 after vector transduction. (Lower right) Virus output in MDMs (donor 4 and donor 8
infection.The distribution of MRJ-L levels seemed to be bimodal in uninfected
general population (Figs. 1c and 2). This observation implicated that the
expression levels of MRJ-L in macrophages may be regulated by geneticdiagram describing the experimental strategy for lentiviral shRNA depletion of MRJ-L in
ncy was about 50–70% as evidenced by a GFP-expressing vector control (Supplementary
Ms) from a healthy donor (donor 6) examined by western blotting. Cells were harvested
tput inMDMs (donor 6) treatedwithMRJ-L-shRNAmeasuredby p24 ELISA at days 4, 7, 10,
e assays. (b) (upper panel) Schematic diagram describing the experimental strategy for
hy donors. (Lower left) Expression proﬁle of MRJ-L by western blot. Cells were harvested
) overexpressing MRJ-L by p24 ELISA at days 4, 8, 12, 16, and 20 post-HIV-1 (M-tropic)
Fig. 5.MRJ-L but not MRJ-S mediates nuclear import of Vpr. (a) Localization of Vpr (tagged with GFP) co-expressed with HA-tagged MRJ-L or MRJ-S. Cells were ﬁxed and stained with an
anti-HA antibody. Bars: 10 μm. (b) Depletion of MRJ-L in HeLa cells by shRNAs shJ10 or shJ8 was veriﬁed by western blotting. N90% knockdown efﬁciency was achieved by shJ8.
(c) Subcellular localization of Vpr (tagged with GFP) in HeLa cells treatedwith shRNA (Scramble) or shRNA (MRJ-L, shJ8). Vpr was not detected in the nucleus whenMRJ-L was depleted.
DAPI staining shows the nuclei. Bars: 10 μm.
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more, in vitro infection of HIV-1 for 8 days did not affect MRJ-L level
in primary macrophages (Fig. 1d). This evidence strongly suggests that
MRJ-L levels should be independent of HIV-1 infection.
Interestingly, macrophages from HIV-1-infected patients had signif-
icantly higher expression of MRJ-L compared with macrophages from
uninfected individuals. We believe that subjects with lower levels of
MRJ-L are less vulnerable to HIV-1 infection because their macrophages
cannot support efﬁcient HIV-1 replication. These individuals may re-
quire repeated exposure, larger inoculums, or more efﬁcient routes of
exposure in order to become infected. In contrast, subjects with high
levels of MRJ-L are more susceptible to HIV-1 infection. Hence, people
with high levels of macrophage MRJ-L are highly represented in the
HIV-1-infected population.
MSM, especially thosewho practice RUAI, are known to be at partic-
ularly high risk for HIV-1 infection (Silan et al., 2013). Our results show
that high levels of MRJ-L in macrophages (41.5 fold) are as strong a risk
factor as anal intercourse (43.9 fold) for HIV-1 acquisition.
MRJ has two isoforms, a large form (MRJ-L or DnaJB6) and a small
form (MRJ-S) (Hanai and Mashima, 2003). The two variants are likely
products of alternatively spliced mRNAs. The large form, MRJ-L, is 326
amino acid long and possesses a nuclear localization signal, while the
small MRJ-S lacks the carboxyl-terminal 95 amino acids of MRJ-L but
contains an additional of 10 amino acids (KEQLLRLDNK). Despite the dif-
ferences at the carboxyl terminus, both isoforms share similar structures
with a conserved J domain (70 amino acids) and a glycine/phenylalanine
domain (Liberek et al., 1991). MRJ-S mainly localizes to the cytoplasm
while MRJ-L distributes both to the cytosol and the nucleus (Cheetham
et al., 1992). It has been suggested that the conserved DNAJ domain wasresponsible for HSP40's ability to inhibit HIV-1 production (Urano et al.,
2013). Our results show that a signiﬁcant correlation is found between
levels of macrophage MRJ-L expression and levels of HIV-1 infection
among high-risk subjects. Therefore, natural variation in MRJ-L levels in
macrophages and unprotected sex behavior may be the major determi-
nants of susceptibility to HIV-1 infection.
Our collective results suggest that individuals with high levels of
MRJ-L may be more susceptible to HIV-1 infection than individuals
with low levels of MRJ-L. We demonstrated that MRJ-L interacts with
HIV-1 Vpr and assists with HIV-1 replication. A rise in MRJ-L levels effec-
tively increases the replication of HIV-1 and a reduction in MRJ-L expres-
sion signiﬁcantly decreases HIV-1 production. Therefore, the variation in
MRJ-L expression in macrophages among different individuals results in
differing susceptibilities to HIV-1 infection. In conclusion, strategies to
lower MRJ-L levels in macrophages may be beneﬁcial in controlling
HIV-1 infection.
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